Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Sep;78(Suppl 4):5–8. doi: 10.1038/bjc.1998.754

Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.

W Jonat 1
PMCID: PMC2062750  PMID: 9741781

Abstract

Current standard adjuvant therapies for early breast cancer include tamoxifen and chemotherapy, depending on the disease prognosis and menopausal status. Luteinizing hormone-releasing hormone (LHRH) analogues offer a different approach to the management of early breast cancer in pre- and perimenopausal women. The most widely studied LHRH analogue is goserelin. It acts on the hypothalamic-pituitary axis to suppress ovarian function, decreasing luteinizing hormone and oestradiol levels to post-menopausal values. Pooled data from 228 premenopausal and perimenopausal patients with advanced breast cancer enrolled in 29 studies worldwide demonstrated an objective response rate for goserelin, 3.6 mg, of 36.4%, with a median duration of response of 44 weeks. These results fall well within the ranges of reported response rates for ovarian ablation and for tamoxifen in similar patient populations. By virtue of its mode of action, goserelin does not stimulate the ovaries and is unlikely to have detrimental effects on the endometrium. In addition, given that goserelin has no oestrogen agonist-like effects, unlike tamoxifen, there is no potential for tumour stimulation in those patients becoming resistant to treatment. Goserelin is generally well tolerated, and the main side-effects are related to ovarian suppression, which is potentially reversible. Preliminary results in premenopausal women with early breast cancer indicate that endocrine treatment with goserelin plus tamoxifen may be as effective as standard combination chemotherapy (cyclophosphamide-methotrexate-5-fluorouracil), but has significantly less acute toxicity. A number of large, randomized trials are now in progress to assess the potential role of goserelin as adjuvant therapy for early breast cancer.

Full text

PDF
5

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barakat R. R. Tamoxifen and endometrial neoplasia. Clin Obstet Gynecol. 1996 Sep;39(3):629–640. doi: 10.1097/00003081-199609000-00012. [DOI] [PubMed] [Google Scholar]
  2. Blamey R. W., Jonat W., Kaufmann M., Bianco A. R., Namer M. Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer. 1992;28A(4-5):810–814. doi: 10.1016/0959-8049(92)90120-q. [DOI] [PubMed] [Google Scholar]
  3. Blamey R. W., Jonat W., Kaufmann M., Bianco A. R., Namer M. Survival data relating to the use of goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer. 1993;29A(10):1498–1498. doi: 10.1016/0959-8049(93)90031-a. [DOI] [PubMed] [Google Scholar]
  4. Boccardo F., Rubagotti A., Perrotta A., Amoroso D., Balestrero M., De Matteis A., Zola P., Sismondi P., Francini G., Petrioli R. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol. 1994 Apr;5(4):337–342. doi: 10.1093/oxfordjournals.annonc.a058837. [DOI] [PubMed] [Google Scholar]
  5. Clayton R. N., Catt K. J. Gonadotropin-releasing hormone receptors: characterization, physiological regulation, and relationship to reproductive function. Endocr Rev. 1981 Spring;2(2):186–209. doi: 10.1210/edrv-2-2-186. [DOI] [PubMed] [Google Scholar]
  6. Coombes R. C., Bliss J. M., Wils J., Morvan F., Espié M., Amadori D., Gambrosier P., Richards M., Aapro M., Villar-Grimalt A. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol. 1996 Jan;14(1):35–45. doi: 10.1200/JCO.1996.14.1.35. [DOI] [PubMed] [Google Scholar]
  7. Harris J. R., Lippman M. E., Veronesi U., Willett W. Breast cancer (2). N Engl J Med. 1992 Aug 6;327(6):390–398. doi: 10.1056/NEJM199208063270606. [DOI] [PubMed] [Google Scholar]
  8. Jonat W., Kaufmann M., Blamey R. W., Howell A., Collins J. P., Coates A., Eiermann W., Jänicke F., Njordenskold B., Forbes J. F. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer. 1995;31A(2):137–142. doi: 10.1016/0959-8049(94)00415-2. [DOI] [PubMed] [Google Scholar]
  9. Misset J. L., di Palma M., Delgado M., Plagne R., Chollet P., Fumoleau P., Le Mevel B., Belpomme D., Guerrin J., Fargeot P. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. J Clin Oncol. 1996 Apr;14(4):1136–1145. doi: 10.1200/JCO.1996.14.4.1136. [DOI] [PubMed] [Google Scholar]
  10. Stewart H. J. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. J Natl Cancer Inst Monogr. 1992;(11):117–120. [PubMed] [Google Scholar]
  11. Thomas E. J., Jenkins J., Lenton E. A., Cooke I. D. Endocrine effects of goserelin, a new depot luteinising hormone releasing hormone agonist. Br Med J (Clin Res Ed) 1986 Nov 29;293(6559):1407–1408. doi: 10.1136/bmj.293.6559.1407-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. West C. P., Baird D. T. Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue. Clin Endocrinol (Oxf) 1987 Feb;26(2):213–220. doi: 10.1111/j.1365-2265.1987.tb00779.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES